Healthcare Industry News: integrase inhibitor
News Release - March 1, 2007
Results from Two Phase III Studies on ISENTRESS(TM) (raltegravir, MK-0518), Merck's Oral Investigational Integrase Inhibitor Presented at the Annual Conference on Retroviruses and Opportunistic Infections (CROI)16-Week Data Showed Significantly Greater Antiretroviral Activity of ISENTRESS in Combination with Optimized Background Therapy (OBT) versus Placebo plus OBT in Treatment-Experienced HIV-Infected Patients ISENTRESS in Combination with OBT Generally Well Tolerated
LOS ANGELES--(HSMN NewsFeed)--Results from two ongoing Phase III studies of ISENTRESS(TM) (raltegravir), an investigational oral integrase inhibitor, demonstrated significantly greater antiretroviral activity of ISENTRESS when used in combination with optimized background therapy (OBT) versus placebo plus OBT in treatment-experienced HIV-infected patients who had failed antiretroviral therapies (ARTs), and who had HIV virus resistant to at least one drug in each of the three available classes of oral ARTs. These data were collected from the 16-week primary analysis time point called for in the 156 week-long study protocol. ISENTRESS has been previously referred to as MK-0518. The brand name ISENTRESS is currently under review by the U.S. Food and Drug Administration (FDA).
In both of these studies, more than 75 percent of patients receiving ISENTRESS (pronounced i-sen-tris) plus OBT achieved viral load (HIV RNA) reductions to less than 400 copies/mL compared to more than 40 percent of patients receiving placebo plus OBT (BENCHMRK-1, 77 percent of patients (N=232) receiving ISENTRESS plus OBT vs. 41 percent of patients (N=118) receiving placebo plus OBT; and BENCHMRK-2, 77 percent of patients (N=230) receiving ISENTRESS plus OBT vs. 43 percent of patients (N=119) receiving placebo plus OBT, p<0.001 for both studies respectively). Both studies also showed that after 16 weeks of treatment, ISENTRESS plus OBT was generally well tolerated. In addition, there were few discontinuations due to adverse experiences (BENCHMRK-1, four patients receiving ISENTRESS plus OBT and four patients receiving placebo plus OBT; for BENCHMRK-2, five patients receiving ISENTRESS plus OBT and one patient receiving placebo plus OBT).
ISENTRESS is under development by Merck & Co., Inc., Whitehouse Station, N.J. These results were presented as late breakers this week at the 14th Annual Conference on Retroviruses and Opportunistic Infections (CROI).
"The efficacy results and tolerability profile that have been seen thus far with ISENTRESS in combination with OBT in this patient population with multi-drug resistant virus are exciting," said David Cooper, M.D., D.Sc., professor of medicine and director, National Centre in HIV Epidemiology and Clinical Research, University of New Wales, Sydney, Australia. "HIV integrase inhibitors may be a new promising class of antiretroviral agents."
ISENTRESS, previously referred to as MK-0518, is the first in a new class of investigational antiretroviral agents called integrase inhibitors that inhibit the insertion of the HIV viral DNA into human DNA. Inhibiting integrase from performing this essential function blocks the ability of the virus to replicate and infect new cells. There are drugs in use that inhibit the other two enzymes - protease and reverse transcriptase - but there are no approved drugs that inhibit integrase.
BENCHMRK-1 and BENCHMRK-2 are ongoing, 156-week, multi-center, triple-blind randomized placebo controlled studies that compare ISENTRESS in combination with OBT to placebo plus OBT in terms of reduction in HIV viral load, change from baseline in CD4 cell counts and evaluation of safety and tolerability. Patients who entered the study had failed antiretroviral therapies as documented by HIV RNA of greater than 1000 copies/mL on stable ARTs for at least two months and were infected with HIV resistant to one or more drugs in each of the three oral classes of ARTs (nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs)).
Patients received ISENTRESS 400mg or placebo, each dosed orally twice daily in combination with OBT. OBT was selected based on patients' prior treatment history and results from HIV resistance testing. In order to allow for the best possible treatment regimen to be constructed for each patient, darunavir and tipranavir, which were investigational ARTs in many countries at the time of this study were allowed to be included in OBT. In addition, patients who were co-infected with Hepatitis B or C were allowed to enroll in these studies.
"We are very encouraged by the results that we've seen from these clinical trials after sixteen weeks of combination therapy with ISENTRESS, as the findings are very similar to what has been observed in Phase II studies," said Roy Steigbigel M.D., professor of medicine, pathology, microbiology and pharmacology, State University of New York at Stony Brook.
16 week results of BENCHMRK-1
Results show that after 16 weeks of therapy, 77 percent of patients (N=232) receiving ISENTRESS in combination with OBT achieved HIV RNA viral load reduction below 400 copies/mL compared to 41 percent of patients (N=118) receiving placebo plus OBT, p<0.001.
In addition, 61 percent of patients receiving ISENTRESS plus OBT achieved viral load reduction to below 50 copies/mL compared to 33 percent of patients receiving placebo plus OBT, p<0.001. Increases in CD4 cell counts from baseline were 83 and 31 cells/mm3 for patients receiving ISENTRESS and for those receiving placebo respectively, p<0.001.
Patients in this study were enrolled in Europe, Asia/Pacific and Peru. The mean baseline viral load was 4.6 log10 copies/mL for the regimen that included ISENTRESS and 4.5 log10 copies/mL for the placebo regimen, respectively. The mean baseline CD4 cell counts were 156 cells/mm3 for the regimen with ISENTRESS and 153 cells/mm3 for the placebo regimen, respectively. These patients had approximately 11 years of prior ARTs; and approximately 90 percent had a diagnosis of AIDS at study entry.
The regimen of ISENTRESS plus OBT was generally well tolerated. There were few discontinuations due to adverse experiences; specifically, for BENCHMRK-1, four patients receiving ISENTRESS plus OBT and four patients receiving placebo plus OBT discontinued therapy. The most commonly reported (reported in at least three percent of patients) study therapy-related side effects were diarrhea, nausea and injection-site reaction (due to enfuvirtide).
16-week results of BENCHMRK-2
Results showed that after 16 weeks of therapy, 77 percent of patients (N=230) receiving ISENTRESS in combination with OBT achieved HIV RNA viral load reduction to below 400 copies/mL compared to 43 percent of patients (N=119) receiving placebo plus OBT alone, p<0.001.
In addition, 62 percent of patients receiving ISENTRESS plus OBT achieved RNA viral load reduction to below 50 copies/mL compared to 36 percent of patients receiving placebo plus OBT, p<0.001. Increases in CD4 cell counts from baseline were 86 and 40 cells/mm3 for the groups receiving ISENTRESS and placebo, respectively, p<0.001. Patients in this study were enrolled in North, Central and South America. The mean baseline viral load was 4.7 log10 copies/mL for both the regimen that included ISENTRESS and the regimen that included placebo, respectively. The mean baseline CD4 cell counts were 146 cells/mm3 for the ISENTRESS regimen and 163 cells/mm3 for the placebo regimen, respectively. These patients had approximately 10 years of prior ARTs; and approximately 90 percent had a diagnosis of AIDS at study entry.
The regimen of ISENTRESS plus OBT was generally well tolerated. There were few discontinuations due to adverse experiences; specifically, for BENCHMRK-2, five patients receiving ISENTRESS plus OBT and one patient receiving placebo plus OBT discontinued therapy. The most commonly reported (reported in at least three percent of patients) study therapy-related side effects were abdominal distension, abdominal pain, diarrhea, flatulence, nausea, injection site reaction (due to enfuvirtide), headache and fatigue.
Prevalence of HIV/AIDS
Despite the availability of drugs to treat HIV/AIDS, the epidemic continues. An estimated 40 million people are currently infected worldwide, and it is estimated that more than four million new infections occur worldwide annually. AIDS is one of the top causes of infectious disease-related mortality worldwide, responsible for approximately three million deaths each year.
Merck HIV research
Merck's efforts to develop investigational treatments and a vaccine against HIV/AIDS have been underway for almost 20 years and continue today. Merck began its HIV integrase inhibitor research in the early 1990's, and Merck was the first to demonstrate integrase strand transfer inhibition and to define the mechanism of action. Merck was also the first to demonstrate inhibition of HIV integrase in vitro and in vivo.
Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck currently discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The Company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service. For more information, visit www.merck.com.
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Merck's business, particularly those mentioned in the cautionary statements in Item 1 of Merck's Form 10-K for the year ended Dec. 31, 2006, and in its periodic reports on Form 10-Q and Form 8-K, which the company incorporates by reference.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.